Submission of the Financial Results for the year ended March 31, 2026
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma reported strong full-year FY2026 results with standalone revenue of ₹1,10,554 million, up ~2.5% YoY, while standalone profit after tax surged 38% to ₹24,148 million from ₹17,468 million in FY2025. Standalone EPS rose to ₹41.58 from ₹29.97. On a consolidated basis, revenue grew 6.4% to ₹3,33,847 million and consolidated PAT increased 0.6% to ₹35,030 million. The company completed an ₹8,000 million share buyback in May 2026 and announced acquisition of Lannett Company LLC (US) subject to regulatory approvals. Exceptional items of ₹173.8 million (standalone) and ₹653.3 million (consolidated) were recorded due to new Indian Labour Codes impacting employee benefit liabilities.
The 38% standalone PAT growth and EPS beat indicate strong operational performance, though modest revenue growth may temper enthusiasm. The completed buyback will support EPS going forward. Shareholders should note ongoing expansion investments and acquisitions that may drive future revenue growth.